Abstract
Aims: Diabetic peripheral neuropathy (DPN) leads to decreased Quality of Life (QoL) and increased risk of depression and anxiety. However, little is known about the impact of concomitant neuropathic pain. Therefore, this study aimed to investigate QoL and mental health in people with diabetes with and without DPN and neuropathic pain.
Methods: 6,962 participants with diabetes participated in this observational, cross-sectional survey study. Participants were grouped into people with (n = 1,601) and without (n=5,361) DPN based on a Michigan Neuropathy Screening Instrument questionnaire (MNSIq)-score ≥ 4. Participants with DPN were subsequently divided into people with (n=1,085) and without (n=516) concomitant neuropathic pain based on a modified Douleur Neuropathique en 4 Questions (DN4)-interview-score ≥ 3. All participants also answered The Short Form Health Survey SF(36) and the Hospital Anxiety and Depression Scale (HADS). Differences between groups were assessed using the Mann-Whitney U-test based on the data type and normality. The level of statistical significance was 0.01. Results are presented as medians with interquartile ranges (IQR).
Results: QoL-, depression- and anxiety scores all differed significantly between participants with and without DPN (all p<0.001). The SF36 medians was 55.1 [36.7;73.6] and 82.2 [63.6;90.9] for the people with and without DPN, respectively, while the HADS depression scores were 4.00 [1;8] and 1.00 [0;3], and the HADS anxiety scores were 5.00 [2;9] and 2.00 [1;5], respectively. For people with DPN and concomitant neuropathic pain, both QoL-, depression-, and anxiety scores were further attenuated with SF36 scores of 50.7 [34.8;69.8] for people with painful DPN and 61.2 [45.2;79.0] for people with painless DPN (p-value <0.001). HADS depression scores were 4.00 [1;8] and 1.00 [0;3], while HADS anxiety scores were 6.00 [3;10] and 4.00 [1;8], respectively (p-value <0.001).
Conclusions: People with DPN have reduced QoL and increased levels of anxiety and depression compared to people with diabetes without DPN. In addition, people with concomitant neuropathic pain have further attenuated QoL, and increased levels of anxiety and depression compared to people with DPN but without concomitant neuropathic pain.
Methods: 6,962 participants with diabetes participated in this observational, cross-sectional survey study. Participants were grouped into people with (n = 1,601) and without (n=5,361) DPN based on a Michigan Neuropathy Screening Instrument questionnaire (MNSIq)-score ≥ 4. Participants with DPN were subsequently divided into people with (n=1,085) and without (n=516) concomitant neuropathic pain based on a modified Douleur Neuropathique en 4 Questions (DN4)-interview-score ≥ 3. All participants also answered The Short Form Health Survey SF(36) and the Hospital Anxiety and Depression Scale (HADS). Differences between groups were assessed using the Mann-Whitney U-test based on the data type and normality. The level of statistical significance was 0.01. Results are presented as medians with interquartile ranges (IQR).
Results: QoL-, depression- and anxiety scores all differed significantly between participants with and without DPN (all p<0.001). The SF36 medians was 55.1 [36.7;73.6] and 82.2 [63.6;90.9] for the people with and without DPN, respectively, while the HADS depression scores were 4.00 [1;8] and 1.00 [0;3], and the HADS anxiety scores were 5.00 [2;9] and 2.00 [1;5], respectively. For people with DPN and concomitant neuropathic pain, both QoL-, depression-, and anxiety scores were further attenuated with SF36 scores of 50.7 [34.8;69.8] for people with painful DPN and 61.2 [45.2;79.0] for people with painless DPN (p-value <0.001). HADS depression scores were 4.00 [1;8] and 1.00 [0;3], while HADS anxiety scores were 6.00 [3;10] and 4.00 [1;8], respectively (p-value <0.001).
Conclusions: People with DPN have reduced QoL and increased levels of anxiety and depression compared to people with diabetes without DPN. In addition, people with concomitant neuropathic pain have further attenuated QoL, and increased levels of anxiety and depression compared to people with DPN but without concomitant neuropathic pain.
| Originalsprog | Engelsk |
|---|---|
| Publikationsdato | 2024 |
| Status | Udgivet - 2024 |
| Begivenhed | 34th annual meeting diabetic neuropathy study group - Rom, Italien Varighed: 5 sep. 2024 → 8 sep. 2024 |
Konference
| Konference | 34th annual meeting diabetic neuropathy study group |
|---|---|
| Land/Område | Italien |
| By | Rom |
| Periode | 05/09/2024 → 08/09/2024 |